UBS Group’s Surface Oncology, Inc. Common Stock SURF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,875
| Closed | -$5.98K | – | 10257 |
|
|
2023
Q2 | $5.98K | Sell |
6,875
-8,930
| -57% | -$6.37K | ﹤0.01% | 7413 |
|
|
2023
Q1 | $11K | Buy |
15,805
+7,492
| +90% | +$6.07K | ﹤0.01% | 7533 |
|
|
2022
Q4 | $6.82K | Sell |
8,313
-53,814
| -87% | -$53.1K | ﹤0.01% | 8983 |
|
|
2022
Q3 | $65K | Sell |
62,127
-118,555
| -66% | -$189K | ﹤0.01% | 6098 |
|
|
2022
Q2 | $297K | Buy |
180,682
+100,246
| +125% | +$208K | ﹤0.01% | 4632 |
|
|
2022
Q1 | $236K | Sell |
80,436
-3,355
| -4% | -$11.8K | ﹤0.01% | 5231 |
|
|
2021
Q4 | $400K | Buy |
83,791
+66,176
| +376% | +$427K | ﹤0.01% | 5166 |
|
|
2021
Q3 | $134K | Buy |
17,615
+3,346
| +23% | +$21.4K | ﹤0.01% | 5621 |
|
|
2021
Q2 | $106K | Buy |
14,269
+2,803
| +24% | +$21.6K | ﹤0.01% | 5835 |
|
|
2021
Q1 | $90K | Buy |
11,466
+3,966
| +53% | +$39.6K | ﹤0.01% | 6045 |
|
|
2020
Q4 | $69K | Buy |
+7,500
| New | +$65.2K | ﹤0.01% | 5933 |
|
|
2019
Q4 | – | Sell |
-1,291
| Closed | -$2K | – | 8521 |
|
|
2019
Q3 | $2K | Buy |
+1,291
| New | +$2.82K | ﹤0.01% | 7770 |
|
|
2019
Q2 | – | Sell |
-2,470
| Closed | -$12K | – | 8256 |
|
|
2019
Q1 | $12K | Buy |
2,470
+427
| +21% | +$2.1K | ﹤0.01% | 6708 |
|
|
2018
Q4 | $9K | Sell |
2,043
-6,352
| -76% | -$49.1K | ﹤0.01% | 7303 |
|
|
2018
Q3 | $92K | Buy |
8,395
+6,913
| +466% | +$81K | ﹤0.01% | 5663 |
|
|
2018
Q2 | $24K | Buy |
+1,482
| New | +$21.4K | ﹤0.01% | 6577 |
|
UBS Group's SURF Position: Q3 2023 in Review
UBS Group sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 6,875 shares — an estimated $5.98K sold.
UBS Group first reported a position in SURF in Q2 2018 and held it in 16 quarters. The position peaked at $400K in Q4 2021. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.
- UBS Group reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- UBS Group sold 6,875 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $5.98K.
- UBS Group first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 16 quarters.
- UBS Group's Surface Oncology, Inc. Common Stock position peaked at $400K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.
Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.